New approaches to pharmacotherapy in patients with stable chronic obstructive pulmonary disease

R. D. Restrepo, D. D. Gardner

    Research output: Contribution to journalArticle

    Abstract

    Chronic obstructive pulmonary disease is predicted to become the third leading cause of death worldwide by the year 2020. Although available evidence-based guidelines facilitate the management of patients with COPD, few therapeutic interventions other than smoking cessation and long-term oxygen therapy have proven to change the course of the disease. New drug development has also proven to be challenging and costly. The development of new once-daily or ultra β2 adrenergic agents, long-acting antimuscarinic agents, and their combination supports the fact that bronchodilators are still considered the mainstay of therapy for COPD. However, a better understanding of the pathophysiology of the disease over the last ten years has resulted in identification of new biologic pathways and the development of novel therapies for patients with COPD that include new anti-inflammatory agents, more effective anti-oxidants, agents that promote lung regeneration, antibiotics, and statin therapy. This manuscript reviews some of the most recent evidence that supports the emerging trends in the pharmacotherapy for the management of patients with stable COPD.

    Original languageEnglish (US)
    Pages (from-to)259-269
    Number of pages11
    JournalMinerva Pneumologica
    Volume49
    Issue number4
    StatePublished - Dec 2010

    Fingerprint

    Chronic Obstructive Pulmonary Disease
    Drug Therapy
    Therapeutics
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Muscarinic Antagonists
    Bronchodilator Agents
    Smoking Cessation
    Oxidants
    Adrenergic Agents
    Regeneration
    Cause of Death
    Anti-Inflammatory Agents
    Guidelines
    Oxygen
    Anti-Bacterial Agents
    Lung
    Pharmaceutical Preparations

    Keywords

    • Anti-inflammatory agents
    • Bronchodilator agents
    • Pulmonary disease, chronic obstructive

    ASJC Scopus subject areas

    • Pulmonary and Respiratory Medicine

    Cite this

    New approaches to pharmacotherapy in patients with stable chronic obstructive pulmonary disease. / Restrepo, R. D.; Gardner, D. D.

    In: Minerva Pneumologica, Vol. 49, No. 4, 12.2010, p. 259-269.

    Research output: Contribution to journalArticle

    Restrepo, R. D. ; Gardner, D. D. / New approaches to pharmacotherapy in patients with stable chronic obstructive pulmonary disease. In: Minerva Pneumologica. 2010 ; Vol. 49, No. 4. pp. 259-269.
    @article{325211b7dc6f438f907649160d52eae8,
    title = "New approaches to pharmacotherapy in patients with stable chronic obstructive pulmonary disease",
    abstract = "Chronic obstructive pulmonary disease is predicted to become the third leading cause of death worldwide by the year 2020. Although available evidence-based guidelines facilitate the management of patients with COPD, few therapeutic interventions other than smoking cessation and long-term oxygen therapy have proven to change the course of the disease. New drug development has also proven to be challenging and costly. The development of new once-daily or ultra β2 adrenergic agents, long-acting antimuscarinic agents, and their combination supports the fact that bronchodilators are still considered the mainstay of therapy for COPD. However, a better understanding of the pathophysiology of the disease over the last ten years has resulted in identification of new biologic pathways and the development of novel therapies for patients with COPD that include new anti-inflammatory agents, more effective anti-oxidants, agents that promote lung regeneration, antibiotics, and statin therapy. This manuscript reviews some of the most recent evidence that supports the emerging trends in the pharmacotherapy for the management of patients with stable COPD.",
    keywords = "Anti-inflammatory agents, Bronchodilator agents, Pulmonary disease, chronic obstructive",
    author = "Restrepo, {R. D.} and Gardner, {D. D.}",
    year = "2010",
    month = "12",
    language = "English (US)",
    volume = "49",
    pages = "259--269",
    journal = "Minerva Pneumologica",
    issn = "0026-4954",
    publisher = "Edizioni Minerva Medica S.p.A.",
    number = "4",

    }

    TY - JOUR

    T1 - New approaches to pharmacotherapy in patients with stable chronic obstructive pulmonary disease

    AU - Restrepo, R. D.

    AU - Gardner, D. D.

    PY - 2010/12

    Y1 - 2010/12

    N2 - Chronic obstructive pulmonary disease is predicted to become the third leading cause of death worldwide by the year 2020. Although available evidence-based guidelines facilitate the management of patients with COPD, few therapeutic interventions other than smoking cessation and long-term oxygen therapy have proven to change the course of the disease. New drug development has also proven to be challenging and costly. The development of new once-daily or ultra β2 adrenergic agents, long-acting antimuscarinic agents, and their combination supports the fact that bronchodilators are still considered the mainstay of therapy for COPD. However, a better understanding of the pathophysiology of the disease over the last ten years has resulted in identification of new biologic pathways and the development of novel therapies for patients with COPD that include new anti-inflammatory agents, more effective anti-oxidants, agents that promote lung regeneration, antibiotics, and statin therapy. This manuscript reviews some of the most recent evidence that supports the emerging trends in the pharmacotherapy for the management of patients with stable COPD.

    AB - Chronic obstructive pulmonary disease is predicted to become the third leading cause of death worldwide by the year 2020. Although available evidence-based guidelines facilitate the management of patients with COPD, few therapeutic interventions other than smoking cessation and long-term oxygen therapy have proven to change the course of the disease. New drug development has also proven to be challenging and costly. The development of new once-daily or ultra β2 adrenergic agents, long-acting antimuscarinic agents, and their combination supports the fact that bronchodilators are still considered the mainstay of therapy for COPD. However, a better understanding of the pathophysiology of the disease over the last ten years has resulted in identification of new biologic pathways and the development of novel therapies for patients with COPD that include new anti-inflammatory agents, more effective anti-oxidants, agents that promote lung regeneration, antibiotics, and statin therapy. This manuscript reviews some of the most recent evidence that supports the emerging trends in the pharmacotherapy for the management of patients with stable COPD.

    KW - Anti-inflammatory agents

    KW - Bronchodilator agents

    KW - Pulmonary disease, chronic obstructive

    UR - http://www.scopus.com/inward/record.url?scp=79851498042&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79851498042&partnerID=8YFLogxK

    M3 - Article

    AN - SCOPUS:79851498042

    VL - 49

    SP - 259

    EP - 269

    JO - Minerva Pneumologica

    JF - Minerva Pneumologica

    SN - 0026-4954

    IS - 4

    ER -